Logo Image
News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShortsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesParkinsonism Practical GuideSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
    • Huntington Disease
  • Neuro-Oncology
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
CMSC 2026|
ATMRD 2026|
Parkinsonism Practical Guide|
CIDP: Grip Strength
Advertisement

Kelvin Tsoi, PhD

Advertisement

Articles by Kelvin Tsoi, PhD

Kelvin Tsoi, PhD: Combination Therapy, Monotherapy in Alzheimer Disease

ByKelvin Tsoi, PhD
August 23rd 2018

After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.

Advertisement

Latest Updated Articles

  • Kelvin Tsoi, PhD: Combination Therapy, Monotherapy in Alzheimer Disease
    Kelvin Tsoi, PhD: Combination Therapy, Monotherapy in Alzheimer Disease

    August 23rd 2018



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis

2

Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM

3

Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action

4

FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis

5

Gene Therapy AMT-260 Shows Early Seizure Reductions in Refractory Mesial Temporal Lobe Epilepsy, Phase 1 Cohort Data Show

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us